Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis

Jaafari, M. R. and Hatamipour, M. and Alavizadeh, S. H. and Abbasi, A. and Saberi, Z. and Rafati, S. and Taslimi, Y. and Mohammadi, A. M. and Khamesipour, A. (2019) Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis. International Journal for Parasitology: Drugs and Drug Resistance, 11. pp. 156-165.

[img] Text
Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.pdf

Download (1MB)


Background: Currently, there is no topical treatment available for any form of cutaneous leishmaniasis (CL) in most of the endemic areas. The aim of the current study was to develop a topical nano-liposomal Amphotericin B (AmB) for the treatment of CL. Methodology/principal findings: Liposomes containing 0.1, 0.2 and 0.4 AmB (Lip-AmB) were formulated and characterized for the size, entrapment efficiency, long term stability, and skin penetration properties using Franz diffusion cells. Liposomes diameters were around 100 nm with no change during more than 20 months’ storage either at 4 °C or at room temperature. Franz diffusion cells studies showed that almost 4 of the applied formulations penetrated across the skin and the highest skin retention (73.92) observed with Lip-AmB 0.4. The median effective doses (ED50), the doses of AmB required to kill 50 of L. major amastigotes were 0.151, 0.151, and 0.0856 (μg/mL) in Lip-AmB 0.1, 0.2, 0.4, respectively. Lip-AmB 0.4 caused 80 reduction in fluorescence intensity of GFP+ L. tropica infected macrophages at 5 μg/mL of AmB concentration. Topical Lip-AmB was applied twice a day for 4 weeks to the skin of BALB/c mice to treat lesions caused by L. major. Results showed the superiority of Lip-AmB 0.4 compared to Lip-AmB 0.2 and 0.1. The parasite was completely cleared from the skin site of infection and spleens at week 8 and 12 post-infection in mice treated with Lip-AmB 0.4. The results suggest that topical Lip-AmB 0.4 may be a useful tool in the treatment of CL and merits further investigation. © 2019

Item Type: Article
Additional Information: Export Date: 16 February 2020 Correspondence Address: Jaafari, M.R.; Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical SciencesIran; email:
Uncontrolled Keywords: BALB/C mice Cutaneous leishmaniasis Leishmania tropica Nano-liposomal amphotericin B Topical treatment amphotericin B amphotericin B deoxycholate animal experiment animal model antileishmanial activity Article controlled study drug formulation drug retention drug stability female in vitro study in vivo study liposomal delivery mouse nanoencapsulation nonhuman parasite load priority journal skin leishmaniasis skin penetration tissue distribution zeta potential
Subjects: QV pharmacology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib1 lib1
Date Deposited: 21 Jun 2020 06:45
Last Modified: 21 Jun 2020 06:45

Actions (login required)

View Item View Item